This is a service of EIN news a digital news provider

Amarantus BioSciences Interview at the 2012 Biotech Showcase

Share |

/EINPresswire.com/ SUNNYVALE, CA - January 20, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, was interviewed at the 2012 Biotech Showcase in San Francisco last week. The interview can be accessed via the following link: http://stocknewsnow.com/?p=2825.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

MEDIA CONTACT:

Lou Levenstein
727.489.9939
info@seraphimstrategies.com


Follow us

image ad

What people say

“We have generated many, many press clippings and improved our SEO ranking from the services that EIN Presswire provides us. Easy and simple way to upload and distribute our press releases. I would recommend their services.”
— Chris Morris, Marketing Manager of Mountz Inc.
“I have been using the EIN Press Release service for more than three years in entertainment & health care industries. Their account managers and the placement of my press releases online has been above reproach reaching mainstream journalists to help further client and brand visibility. I highly recommend this service for global notoriety and am thankful I made that first call.“
— Monica Anders PR Strategist 25 Years!

Our Partners

Press releases

see all press releases »